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Objective: This study evaluated in vitro differentiation of mesenchymal stromal cells isolated
from bone marrow, in tenocytes after treatment with bovine tendon extract.
Methods: Bovine tendons were used for preparation of the extract and were stored at −80 ◦C.
Mesenchymal stromal cells from the bone marrow of three donors were used for cytotoxicity
tests by means of MTT and cell differentiation by means of qPCR.
Results: The data showed that mesenchymal stromal cells from bone marrow treated for
up  to 21 days in the presence of bovine tendon extract diluted at diminishing concentra-
tions (1:10, 1:50 and 1:250) promoted activation of biglycan, collagen type I and ﬁbromodulin
expression.
Conclusion: Our results show that bovine tendon extract is capable of promoting differenti-
ation of bone marrow stromal cells in tenocytes.
©  2015 Sociedade Brasileira de Ortopedia e Traumatologia. Published by Elsevier Editora
Ltda. All rights reserved.
Células  mesenquimais  do  estroma  da  medula  óssea  tratadas  com  extrato
de  tendão  bovino  adquirem  o  fenótipo  de  tenócitos  maduros
Palavras-chave:
Tendão
r  e  s  u  m  o
Objetivo: O estudo avalia a diferenciac¸ão in vitro das células mesenquimais isoladas do
estroma da medula óssea em tenócitos após tratamento com extrato de tendão bovino.
Células mesenquimais do estroma Métodos: Tendões bovinos foram usados para confecc¸ão do extrato e estocados a −80 ◦C.
is do estroma da medula óssea (BMSCs) de três doadores foram usadasda medula óssea Células mesenquima
Tenócitos para  os testes de citotoxicidade por MTT e diferenciac¸ão celular por qPCR.
Resultados: Os dados mostram que células mesenquimais do estroma da medula óssea
tratadas por até 21 dias em presenc¸a do extrato de tendão bovino diluído em concentrac¸ões
 Work developed at the Instituto Nacional de Traumatologia e Ortopedia (INTO), Rio de Janeiro, RJ, Brazil.
∗ Corresponding author.
E-mails: liviiaaugusto@gmail.com, livia augusto@hotmail.com (L.M.M. Augusto).
http://dx.doi.org/10.1016/j.rboe.2015.12.013
2255-4971/© 2015 Sociedade Brasileira de Ortopedia e Traumatologia. Published by Elsevier Editora Ltda. All rights reserved.
r e v b r a s o r t o p . 2 0 1 6;5 1(1):70–74 71
crescentes (1:10, 1:50 e 1:250) promovem a ativac¸ão da expressão de biglican, colágeno tipo
I  e ﬁbromodulina.
Conclusão: Nossos resultados mostram que o extrato de tendão bovino é capaz de promover
a  diferenciac¸ão das BMSCs em tenócitos.
©  2015 Sociedade Brasileira de Ortopedia e Traumatologia. Publicado por Elsevier











































endons are a specialized type of tissue composed of
enoblasts and tenocytes, which are embedded in an extra-
ellular matrix mostly composed of type I collagen. Tenocytes
nly have limited potential for proliferation and thus confer
ow regenerative capacity on tendons.1,2
Tendon injuries constitute a serious problem within
rthopedic practice and generate high costs for the public
ealthcare system, as well as having an impact on the quality
f life of the patients affected. Although regeneration is the
im of the clinical treatments used, the methods currently
vailable continue to be ineffective. Thus, tendon dysfunc-
ions lead to deﬁnitive physical incapacity.3–5
Mesenchymal cells isolated from bone marrow stromal
ells (BMSCs) are known to be a promising therapeutic option
ithin the ﬁeld of cell therapy and bioengineering of muscu-
oskeletal tissues.5–8 Their use in association with synthetic
iomaterials has been proposed as an option for modern
reatments aiming to toward tendon reconstruction, using an
llograft, autograft or xenograft.9,10 Use of autologous BMSCs
iosynthetic grafts has the aims of improving the results from
onservative surgery and reducing the time taken for the pre-
njury biomechanical properties to be restored.11 Furthermore,
he low immunogenicity of BMSCs makes it possible to use
hem allogeneically and minimizes the need for immunosup-
ression of the receptor.12
Despite the signiﬁcant therapeutic potential of BMSCs,
ittle is yet known about the mechanisms and signaling path-
ays involved in determining that BMSCs will differentiate
oward a tenogenic route, or in relation to progression of
heir differentiation. Considering that BMSCs seem to respond
o stimuli that are present in extracts from healthy mature
issues and have speciﬁc phenotypic characteristics,13,14 we
eveloped the hypothesis that tendon extracts might induce
ifferentiation of BMSCs into tenocytes. Thus, the present
tudy had the objective of evaluating the inﬂuence of treat-
ent of human BMSCs with different concentrations of bovine
endon extract, on in vitro differentiation toward a tenocytic
oute.
aterial  and  methods
solation  and  expansion  of  mesenchymal  cells  from  the
troma  of  human  bone  marrowMSCs were isolated from surgical waste that originated
rom hip arthroplasty procedures on ﬁve patients (two men
nd three women) aged 45–60 years, who did not presentany comorbidities. Informed consent was obtained from all
of these individuals after approval of the study protocol
by the institutional ethics committee. After the samples
had been collected in the surgical center, they were stored
in sterile ﬂasks containing Iscove’s modiﬁed Dulbecco’s
medium (IMDM; Sigma–Aldrich, St. Louis, MO, USA), sup-
plemented with 20% bovine fetal serum (BFS; Gibco, Grand
Island, NY, USA), at 4 ◦C for not more  than 18 h. To isolate
the total cellular fraction, the bone marrow was resus-
pended in phosphate-buffered saline (PBS) solution and was
mechanically dissociated from any bone fragments. The cell
suspensions thus obtained were collected in 50 mL  tubes and
were centrifuged at 836 × g and 4 ◦C for 5 min. The cells were
then resuspended in 50 mL  of IMDM supplemented with 20%
BFS and were counted using a Neubauer chamber. Following
this, 6 × 105 mononuclear cells were distributed in culturing
ﬂasks of volume 75 cm2, in 10 mL  of IMDM with 20% BFS, and
were maintained at 37 ◦C under 5% CO2. Three days later, the
non-adherent fraction was removed by means of lavage with
PBS and the culturing medium was changed. After a further 14
days, the cells were removed using a solution of 0.125% trypsin
and 0.78 mM EDTA and were expanded.
Preparation  of  bovine  tendon  extract
Five bovine calcaneal tendons were obtained. They were
macerated mechanically and then were ground up using an
electric blender of power 20 W,  in the proportions of 1 g of tis-
sue to 2 mL  of IMDM, without BFS.15 The tissue extract was◦C
centrifuged at 836 × g and 8 ◦C for 5 min  and was then stored
at −80 ◦C for a maximum of two months.
Analysis  of  cell  viability  using  the  MTT  method
BMSCs were cultured on 24-well plates, at a density of
2.5 × 104 cells/well and were treated with bovine tendon
extract diluted in the proportions of 1:10, 1:50 or 1:250 (v/v) in
IMDM supplemented with 10% BFS. Cell viability was assessed
24, 72, 120 and 168 hours after the treatment, in the presence of
MTT  (thiazolyl blue tetrazolium bromide; Sigma–Aldrich) at a
concentration of 25 mg/mL. Equal concentrations of dimethyl
sulfoxide (DMSO) were used as a negative control. Colorimet-
ric evaluation was performed at a wavelength of 550 nm,  using
the SIRIO S SEAC reader (Burladingen, Germany).
Analysis  of  gene  expression  using  qPCRBMSCs were cultured under the different experimental con-
ditions described above (1:10, 1:50 or 1:250, v/v), for 7, 14
or 21 days. The cells were then washed and the total RNA
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Table 1 – Target genes and designs of the primers used in analyzing gene expression.
Target gene Access number Sequence (5′–3′) Product (bp)
COL1A1 NM 000088.3 Sense GTGCTCCTGGTATTGCTGGT 150
Antisense GCTCTCCCTTAGCACCAGTGT
BGN NM 001711.4 Sense TGAAGTCTGTGCCCAAAGAGA 157
Antisense GCCTTCTCATGGATCTTGGA
FMOD NM 002023.4 Sense CAACACCTTCAATTCCAGCA 178
Antisense CTGCAGCTTGGAGAAGTTCA
ACTB NM 001101.3 Sense TACAATGAGCTGCGTGTGG 165
Antisense AGAGGCGTACAGGGATAGCA
, beta
capable of inducing expression of the genes implicated in
tenocytic differentiation of mesenchymal stem cells. Further-
more,  the tendon protein extract promoted induction in aCOL1A1, type 1A collagen; BGN, biglycan; FMOD, ﬁbromodulin; ACTB
was extracted using the Trizol® method (Invitrogen Corp.,
Carlsbad, CA, USA) and was treated using DNase (Ambion®
DNA-freeTM DNase treatment; Life Technologies), in accor-
dance with the manufacturer’s instructions. The integrity and
quantity of the RNA were evaluated by means of electrophore-
sis on denaturing gel and by means of spectrophotometry
(NanodropTM 1000; Thermo Fisher Scientiﬁc, Inc.). Reverse
transcription for synthesis of complementary DNA (cDNA)
was performed in duplicate, from 1.0 g of RNA, using the
ImProm-IITM reverse transcription system (Promega), in accor-
dance with the manufacturer’s protocol. qPCR was performed
using the Power Sybr Green Master MIX® detection sys-
tem (Applied Biosystems, Molecular Probes, Inc.) in the Step
One equipment (Applied Biosystems, Molecular Probes, Inc.).
Primers from the constitutive genes (rDNA 28S and actin) were
used as controls for the experiment. The expression of the
genes for type I collagen, biglycan and ﬁbromodulin was nor-
malized in relation to the expression of the constitutive gene
for -actin (Table 1). The 2−CT13 method was used for analyz-
ing the expression of the target genes of this study in relation
to the constitutive gene. The values for relative expression that
have been presented took the ﬁxed control-group value of 1.0


























Fig. 1 – Evaluation of the cytotoxicity of bovine tendon
extract in mesenchymal cells of the bone marrow stroma. C
represents control condition; 1:10, 1:50 and 1:250 represent
the dilutions of the bovine tendon extract in IMDM;  B
represents the control condition for the technique in which
there were  no cells. Under all conditions, IMDM was used
with supplementation with 1% BFS. actin; bp, size of ampliﬁed product in base pairs.
Results
With the aim of evaluating the toxicity of bovine tendon
extract toward BMSCs, the MTT test was performed. The
results showed that the bovine tendon extract did not alter
the viability of the BMSCs at any of the concentrations tested
(Fig. 1). Thus, we  can infer that the bovine tendon extract did
not have any cytotoxic effect on the mesenchymal stem cells.
Given that there was no cytotoxic effect, the potential of the
bovine tendon extract for differentiation was tested with the
aim of evaluating whether the growth factors present in the
extract would stimulate differentiation of the mesenchymal
progenitor cells. We observed that in the BMSCs, the extract
was capable of activating expression of the genes for type
I collagen (Fig. 2), biglycan (Fig. 3) and ﬁbromodulin (Fig. 4)
over periods of 7, 14 and 21 days. These results showed that


































Fig. 2 – Gene expression of type I collagen in mesenchymal
cells of the bone marrow stroma, treated with increasing
concentrations of bovine tendon extract (1:10, 1:50 and
1:250). Data normalized in relation to the expression of the
constitutive gene ACTB.

































Fig. 3 – Evaluation of biglycan expression through qPCR on
mesenchymal stromal cells treated with increasing




































Fig. 4 – Evaluation of ﬁbromodulin expression through
qPCR on mesenchymal stromal cells treated with















Schieker M, et al. Conversion of human bone marrow-derived:50 and 1:250).
ose-dependent manner and as a function of the duration of
xposure to the extract.
iscussion
ur study showed that the bovine tendon extract had the
otential to induce tenocytic differentiation of BMSCs and that
his extract did not have cytotoxicity at any of the concen-
rations used. In our analyses, the results showed that there
as a spatial and temporal window for success regarding
ifferentiation of BMSCs into tenocytes. We emphasize that
or the procedure to be efﬁcient, the BMSCs (at 70% conﬂu-
nce) should be treated with tendon extract at 1:50 for seven
ays. We  observed that the peak expression of biglycan and 6;5 1(1):70–74 73
ﬁbromodulin (which are markers for tenocytes)16–21 was at this
time. This indicated that the BMSCs became committed to a
tenocytic lineage. The treatment protocol needs to proceed
with increased concentration of the extract, which should be
1:10 for another 10 days. This allows the BMSCs to maintain
type I collagen expression and provide an efﬁcient extracellu-
lar matrix, so as also to maintain cell viability.
Our results suggest that in tendons, there are growth fac-
tors that stimulate differentiation of pluripotent cells into
tendon cells. This opens up a possibility for the ﬁeld of cell
therapy, for treating tendinopathy. Finally, the potential was
evaluated in an in vitro model and therefore there is a need for
validation in an in vivo model, in order to conﬁrm the results.
Moreover, we  raise the possibility that, in the future, the poten-
tial of tendon extracts originating from human tendons in
cadaver donors might be evaluated.
Conclusions
The set of results showed that treatment of BMSCs with a
protein extract from bovine tendon tissue promoted differen-
tiation into tenocytes.
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